Last edition
News about "Torsten Türling"
Syntegon Posts Record Year in 2025 and Aims for Further Growth
Syntegon reports a record 2025 with revenue up 10 percent to €1.75 billion and pharma sales surging 22 percent, alongside strong EBITDA and cash flow growth, reinforcing its position as a key lifecycle partner for pharma, biotech and food industries.
Torsten Türling | 21/04/2026 | By News Bureau | 200
CVC and Apollo Partner to Accelerate Syntegon's Next Growth Phase
CVC has reaffirmed its confidence in Syntegon’s growth strategy as Apollo acquires a 37 percent minority stake to support expansion—particularly in the US—following strong performance that saw revenue reach a record €1.75 billion and operating profit quadruple, with further growth planned under CEO Torsten Türling.
Torsten Türling | 23/03/2026 | By News Bureau | 106
Syntegon Posts Strong Q3 Performance with Accelerating Pharma Growth and Higher Profit Margins
Syntegon recorded double-digit growth in sales and profitability, supported by strong pharma demand, new technology launches, and continued operational improvements.
Torsten Türling | 24/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy